Merck Inc. to acquire Rigontec GmbH and with it RGT 100 which is currently in Phase I/II in advanced solid tumors .

Merck Inc. and Rigontec GmbH announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec�s lead candidate, RGT 100, is currently in Phase I development evaluating treatment in patients with various tumors. Under the terms of the agreement, Merck, through a subsidiary, will make an upfront cash payment of �115 million to Rigontec�s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, Merck may make additional contingent payments of up to �349 million. The transaction is subject to certain closing conditions.